fda warning letters compounded glp-1 september 2025 Drug Recalls and Warnings: Recalls for Semaglutide and Tirzepatide, Wegovy; Facility FDA issued 30 warning letters
Description
Were finalizing those data now, which look quite promising
The consistency across doses suggests this is not simply a downstream effect of weight loss but may represent a direct pharmacological action on inflammatory pathways
These medications have become game-changers for weight loss and diabetes management, especially for patients who have struggled with traditional methods
Moreover, conditioned media from activated fibroblasts and exogenous lactate have been shown to trigger the expression of profibrotic genes in macrophages by inducing histone lactylation [17]
